Decreased Risk of Coronavirus Disease 2019-Related Hospitalization Associated With the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2022 Jul 22

PMID 35866102

Authors

Jessica P Ridgway

Samuel Tideman

Bill Wright

Ari Robicsek

Affiliations

Soon will be listed here.

Abstract

Among 134 223 patients with coronavirus disease 2019 (COVID-19), we assessed how risk of hospitalization changed at different intervals in the pandemic, controlling for prior COVID-19 immunity. In multivariable analysis, outpatients with COVID-19 during the Omicron-predominant time period had significantly lower odds of hospitalization compared to pre-Delta (adjusted odds ratio, 0.26 [95% confidence interval, .22-.32]).

Citing Articles

Comparison between available early antiviral treatments in outpatients with SARS-CoV-2 infection: a real-life study.

Rinaldi M, Campoli C, Gallo M, Marzolla D, Zuppiroli A, Riccardi R BMC Infect Dis. 2023; 23(1):646.

PMID: 37784051 PMC: 10546723. DOI: 10.1186/s12879-023-08538-9.

Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.

Tiseo G, Barbieri C, Galfo V, Occhineri S, Matucci T, Almerigogna F Infect Dis Ther. 2022; 12(1):257-271.

PMID: 36441485 PMC: 9707131. DOI: 10.1007/s40121-022-00729-2.

References

Modes M, Directo M, Melgar M, Johnson L, Yang H, Chaudhary P . Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021,.... MMWR Morb Mortal Wkly Rep. 2022; 71(6):217-223. PMC: 8830624. DOI: 10.15585/mmwr.mm7106e2. View

Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B . Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA. 2021; 327(6):583-584. PMC: 8719272. DOI: 10.1001/jama.2021.24868. View

Rossler A, Riepler L, Bante D, von Laer D, Kimpel J . SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022; 386(7):698-700. PMC: 8781314. DOI: 10.1056/NEJMc2119236. View

Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C . Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022; 22(7):959-966. PMC: 9033213. DOI: 10.1016/S1473-3099(22)00141-4. View

Nyberg T, Ferguson N, Nash S, Webster H, Flaxman S, Andrews N . Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022; 399(10332):1303-1312. PMC: 8926413. DOI: 10.1016/S0140-6736(22)00462-7. View